Citius Oncology, Inc. (NASDAQ: CTOR)

TenX Keane Acquisition (TENK) operates in the acquisition industry, with a specific focus on entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities, primarily in Asia. The company, established on March 1, 2021, and led by CEO Xiaofeng Yuan, has raised capital through an initial public offering (IPO) and a private placement, amassing $66 million in gross proceeds from the IPO alone.

TenX Keane Acquisition's primary business activities revolve around identifying and acquiring a target business in Asia, specifically in the healthcare industry. The company's management team, including CFO Taylor Zhang and Independent Directors Cathy Jiang, Joel Mayersohn, and Brian Hartzband, brings extensive experience in finance, operations, asset management, banking, and business development. This experienced team, coupled with the company's established deal sourcing network and status as a publicly listed acquisition company, provides a competitive edge in the acquisition industry.

The company generates revenue through the completion of business combinations, improving the efficiency of operations, and implementing strategies to scale revenue organically and/or through acquisitions. TenX Keane Acquisition's acquisition criteria include a strong management team, revenue and earnings growth potential, potential for strong free cash flow generation, and benefits from being a public company. The company's recent agreement and plan of merger and reorganization with Citius Pharmaceuticals, Inc. and its subsidiary, Citius Oncology, Inc., exemplify its acquisition strategy.

As an emerging growth company, TenX Keane Acquisition is eligible for certain exemptions from various reporting requirements. However, the company is subject to the Holding Foreign Companies Accountable Act (HFCAA), which could result in delisting or trading prohibitions if the Public Company Accounting Oversight Board (PCAOB) is unable to conduct inspections or full investigations of the company's auditor, Marcum LLP. Despite these potential challenges, TenX Keane Acquisition remains committed to its mission of identifying and acquiring a target business in Asia, leveraging its experienced management team, established deal sourcing network, and status as a publicly listed acquisition company to create shareholder value.

In terms of products and services, TenX Keane Acquisition primarily offers acquisition and merger services. The company's brand names and trade names include TenX Keane Acquisition and TENK. Through these services, the company aims to improve operational efficiency and drive revenue growth for its target businesses, ultimately benefiting shareholders and the broader healthcare industry in Asia.